IPO Centre     27-Jul-21
IPO News
Glenmark Life Sciences IPO subscribed 2.78 times
The issue received bids for 4.17 crore shares as against 1.50 crore shares on offer.

The initial public offer of bulk drug and contract manufacturer Glenmark Life Sciences received bids for 4.17 crore shares as against 1.50 crore shares on offer on Tuesday (27 July 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 2.78 times.

The issue opened for bidding on Tuesday (27 July 2021) and it will close Thursday (29 July 2021). The price band of the IPO is fixed at Rs 695-720 per share. An investor can bid for a minimum of 20 equity shares and in multiples thereof.

The IPO comprises of fresh issue of equity shares worth up to Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares by existing shareholder Glenmark Pharmaceuticals.

Glenmark Pharmaceuticals is the promoter of the company, which currently holds an aggregate of 10,78,04,950 equity shares, aggregating to 100% of the pre-offer issued and paid-up equity share capital. The post IPO shareholding for the same is expected to be around 82.84%.

The proceeds from the issue will be used for payment of Rs 800 crore of outstanding purchase consideration to the Promoter Glenmark Pharmaceutical for the spin-off of the API business through business purchase agreement, funding the capital expenditure requirements of Rs 152.7 crore and remaining amount will be used for general corporate purposes.

Ahead of the IPO, Glenmark Life Sciences on 26 July 2021 allotted 63,06,660 equity shares to 19 anchor investors, at Rs 720 per equity share, aggregating to Rs 454.07 crore.

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

The API portfolio of the company comprises of specialized and profitable products which includes niche and technically complex molecules. The company has the capacity to branch into other high value products. As of 31 December 2020, the company had a portfolio of 120 molecules globally.

Glenmark Life Sciences reported a net profit of Rs 351.58 crore and sales of Rs 1,885.17 crore in the twelve months ended 31 March 2021.

Previous News
  Glenmark Life Sciences announces board meeting date
 ( Corporate News - 20-Apr-23   10:39 )
  Board of Glenmark Life Sciences recommends interim dividend
 ( Corporate News - 11-Nov-21   10:35 )
  Glenmark Life Sciences to announce Quarterly Result
 ( Corporate News - 01-Feb-22   13:34 )
  Board of Glenmark Life Sciences recommends Final Dividend
 ( Corporate News - 21-Apr-22   09:40 )
  Glenmark Life Sciences standalone net profit declines 33.08% in the March 2024 quarter
 ( Results - Announcements 25-Apr-24   15:45 )
  Glenmark Life Sciences announces board meeting date
 ( Corporate News - 10-Mar-23   10:39 )
  Glenmark Life Sciences standalone net profit rises 58.96% in the September 2021 quarter
 ( Results - Announcements 11-Nov-21   08:10 )
  Glenmark Life Sciences announces board meeting date
 ( Corporate News - 14-Oct-23   14:55 )
  Glenmark Life Sciences fixes record date for interim dividend
 ( Market Beat - Reports 15-Mar-23   09:22 )
  Glenmark Life Sciences to conduct board meeting
 ( Corporate News - 02-Nov-21   16:28 )
  Glenmark Pharma divests 75% stake in Glenmark Life Sciences to Nirma
 ( Corporate News - 21-Sep-23   19:38 )
Other Stories
  Ixigo IPO ends with blockbuster subscription
  13-Jun-24   16:12
  Ixigo IPO subscribed 98.10 times
  12-Jun-24   17:36
  Ixigo IPO subscribed 9.31 times
  11-Jun-24   17:35
  Ixigo IPO subscribed 1.95 times
  10-Jun-24   17:06
  Kronox Lab Sciences IPO ends with stellar subscription
  06-Jun-24   16:08
  Kronox Lab Sciences IPO subscribed 117.25 times
  05-Jun-24   17:35
  Kronox Lab Sciences IPO subscribed 24.57 times
  04-Jun-24   17:17
  Kronox Lab Sciences IPO subscribed 11.06 times
  03-Jun-24   17:21
  Awfis Space Solutions IPO ends with stellar subscription
  28-May-24   16:55
  Awfis Space Solutions IPO subscribed 108.17 times
  27-May-24   17:37
Back Top